CM Life Sciences, Inc. (CMLF)
Price:
11.60 USD
( - -0.88 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Churchill Capital Corp X Warrants
VALUE SCORE:
7
2nd position
M3-Brigade Acquisition V Corp. Units
VALUE SCORE:
11
The best
Horizon Kinetics SPAC Active ETF
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
CM Life Sciences, Inc. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company was founded in 2020 and is based in New York, New York.
NEWS
CM Life Sciences and Sema4 Announce Release of Definitive Proxy Statement for July 21 Shareholder Meeting to Vote on Business Combination
businesswire.com
2021-07-02 12:15:00NEW YORK--(BUSINESS WIRE)--CM Life Sciences (Nasdaq: CMLF), a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, has filed its definitive proxy statement with the Securities and Exchange Commission (the “SEC”) in connection with the previously announced proposed business combination with Sema4. The definitive proxy statement contains important information about the proposed business combination contemplated by the Agreement and
3 Stocks Cathie Wood Keeps Buying
thedogofwallstreet.com
2021-06-12 12:10:00After every trading session, Ark Invest's Cathie Wood shows which stocks she has bought and sold throughout the day.
Sema4 and CM Life Sciences Announce the Filing of Amended Preliminary Proxy Statement
businesswire.com
2021-06-10 17:12:00STAMFORD, Conn.--(BUSINESS WIRE)---- $CMLF #AI--The filing of the amended proxy statement marks the next step in the formal Securities and Exchange Commission (SEC) review process.
Cathie Wood's ARK Invest Buys Over 330,000 Shares of CM Life Sciences
247wallst.com
2021-05-27 09:55:06One of ARK Invest exchange-traded funds run by ETF star Cathie Wood bought over 330,000 shares of CM Life Sciences Inc.
Sema4 and CM Life Sciences Announce the Filing of the Schedule-14A Proxy Statement in Connection with the Proposed Merger
businesswire.com
2021-05-06 17:31:00STAMFORD, Conn.--(BUSINESS WIRE)---- $CMLF #AI--Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, and CM Life Sciences (Nasdaq: CMLF), a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today announced the filing of the preliminary proxy statement related to their proposed business combination. The filing of the preliminary proxy statement initiates the formal Securitie
CM Life Sciences Announces Filing of Amended Annual Report on Form 10-K Relating to Restatement of Financial Statements in Accordance with Recent SEC Guidance
businesswire.com
2021-05-05 06:10:00NEW YORK--(BUSINESS WIRE)--CM Life Sciences, Inc. (NASDAQ:CMLF) today announced that it has filed with the Securities and Exchange Commission (SEC) an amended annual report on Form 10-K/A and a Form 8-K reporting the restatement of certain of its previously issued financial statements. The restatement was following a statement issued on April 12, 2021 by the Acting Director of the Division of Corporation Finance and the Acting Chief Accountant of the SEC relating to reporting considerations for
CM Life Sciences II: SomaLogic Is Great, But Post-Merger SPAC Dilution Should Frighten Investors
seekingalpha.com
2021-04-01 03:59:28CM Life Sciences II, Inc. is the second life-sciences-focused special purpose acquisition company from the Casdin-Meisters team launched in Feb 2021.
CM Life Sciences: SPAC Acquires Sema4, A Promising AI Health Intelligence Co.
seekingalpha.com
2021-02-23 14:12:57CM Life Sciences, Inc. is a life-sciences-focused special purpose acquisition company founded in July 2020 aiming to deploy $443M in raised cash to acquire a private company. CM LS selected their target, Sema4, a revenue-producing ('20: $190M|38% CAGR) health intelligence company with ~1K employees aiming to advance healthcare via a suite of next-gen diagnostics utilizing data-driven platform-insights.
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of CM Life Sciences, Inc. - CMLF
prnewswire.com
2021-02-12 21:00:00NEW YORK, Feb. 12, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is...
CMLF Stock Price Increases Over 80% Over The Past Week: Why It Happened
pulse2.com
2021-02-12 13:21:35The stock price of CM Life Sciences Inc (NASDAQ: CMLF) is trading up over 80% over the past week. This is why it happened.
CMLF Stock Price Hit A Day High Of Over 65.9%: Why It Happened
pulse2.com
2021-02-10 14:25:41The stock price of CM Life Sciences Inc (NASDAQ: CMLF) hit a day high of more than 65%. This is why it happened.
No data to display
CM Life Sciences and Sema4 Announce Release of Definitive Proxy Statement for July 21 Shareholder Meeting to Vote on Business Combination
businesswire.com
2021-07-02 12:15:00NEW YORK--(BUSINESS WIRE)--CM Life Sciences (Nasdaq: CMLF), a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, has filed its definitive proxy statement with the Securities and Exchange Commission (the “SEC”) in connection with the previously announced proposed business combination with Sema4. The definitive proxy statement contains important information about the proposed business combination contemplated by the Agreement and
3 Stocks Cathie Wood Keeps Buying
thedogofwallstreet.com
2021-06-12 12:10:00After every trading session, Ark Invest's Cathie Wood shows which stocks she has bought and sold throughout the day.
Sema4 and CM Life Sciences Announce the Filing of Amended Preliminary Proxy Statement
businesswire.com
2021-06-10 17:12:00STAMFORD, Conn.--(BUSINESS WIRE)---- $CMLF #AI--The filing of the amended proxy statement marks the next step in the formal Securities and Exchange Commission (SEC) review process.
Cathie Wood's ARK Invest Buys Over 330,000 Shares of CM Life Sciences
247wallst.com
2021-05-27 09:55:06One of ARK Invest exchange-traded funds run by ETF star Cathie Wood bought over 330,000 shares of CM Life Sciences Inc.
Sema4 and CM Life Sciences Announce the Filing of the Schedule-14A Proxy Statement in Connection with the Proposed Merger
businesswire.com
2021-05-06 17:31:00STAMFORD, Conn.--(BUSINESS WIRE)---- $CMLF #AI--Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, and CM Life Sciences (Nasdaq: CMLF), a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today announced the filing of the preliminary proxy statement related to their proposed business combination. The filing of the preliminary proxy statement initiates the formal Securitie
CM Life Sciences Announces Filing of Amended Annual Report on Form 10-K Relating to Restatement of Financial Statements in Accordance with Recent SEC Guidance
businesswire.com
2021-05-05 06:10:00NEW YORK--(BUSINESS WIRE)--CM Life Sciences, Inc. (NASDAQ:CMLF) today announced that it has filed with the Securities and Exchange Commission (SEC) an amended annual report on Form 10-K/A and a Form 8-K reporting the restatement of certain of its previously issued financial statements. The restatement was following a statement issued on April 12, 2021 by the Acting Director of the Division of Corporation Finance and the Acting Chief Accountant of the SEC relating to reporting considerations for
CM Life Sciences II: SomaLogic Is Great, But Post-Merger SPAC Dilution Should Frighten Investors
seekingalpha.com
2021-04-01 03:59:28CM Life Sciences II, Inc. is the second life-sciences-focused special purpose acquisition company from the Casdin-Meisters team launched in Feb 2021.
CM Life Sciences: SPAC Acquires Sema4, A Promising AI Health Intelligence Co.
seekingalpha.com
2021-02-23 14:12:57CM Life Sciences, Inc. is a life-sciences-focused special purpose acquisition company founded in July 2020 aiming to deploy $443M in raised cash to acquire a private company. CM LS selected their target, Sema4, a revenue-producing ('20: $190M|38% CAGR) health intelligence company with ~1K employees aiming to advance healthcare via a suite of next-gen diagnostics utilizing data-driven platform-insights.
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of CM Life Sciences, Inc. - CMLF
prnewswire.com
2021-02-12 21:00:00NEW YORK, Feb. 12, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is...
CMLF Stock Price Increases Over 80% Over The Past Week: Why It Happened
pulse2.com
2021-02-12 13:21:35The stock price of CM Life Sciences Inc (NASDAQ: CMLF) is trading up over 80% over the past week. This is why it happened.
CMLF Stock Price Hit A Day High Of Over 65.9%: Why It Happened
pulse2.com
2021-02-10 14:25:41The stock price of CM Life Sciences Inc (NASDAQ: CMLF) hit a day high of more than 65%. This is why it happened.